

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Donogh P. O'Brien et al.</p> <p>Serial No.: not yet assigned</p> <p>Filed: August 8, 2001</p> <p>For: METHOD AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MYOCARDIAL INFARCTION</p>	<p>Group Art Unit: not yet assigned</p> <p>Examiner: not yet assigned</p> <p>EXPRESS MAIL LABEL NO. EL 895 375 294 US</p>
---	---

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to the examination of this application on its merits, please consider and enter into the file associated with its examination the following amendments and remarks.

In the Specification:

Please replace the paragraph beginning at page 1, line 16, with the following rewritten paragraph:

--This application is a continuation application under 37 C.F.R. §1.53 (b) (1) claiming priority to co-pending application Serial No. 08/476,837 filed on 7 June 1995, which is a continuation of Serial No. 08/260,662 filed on 16 June 1994, which is a continuation of Serial No. 08/076,280 filed on 11 June 1993, which is a continuation of Serial No. 07/887,575 filed on 18 May 1992, which is a continuation in part of Serial No. 07/237,595 filed on 25 August 1988 which is a continuation in part of Serial No. 07/209,665 filed on 21 June 1988 which is a continuation in part of Serial No. 06/926,977 filed 4 November 1986 which applications are incorporated herein by reference.--

In the Claims:

Please cancel claim 1.

Please add the following new claim:

18. (NEW) A method of treating a coagulation disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a tissue factor protein antagonist comprising lipoprotein associated coagulation inhibitor ("LACI").

18. (NEW) A method of treating a coagulation disorder in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a tissue factor protein antagonist comprising lipoprotein associated coagulation inhibitor ("LACI").

Serial No.: not yet assigned

REMARKS

The specification has been amended to add reference to applications to which the instant application claims the benefit of priority.

Claims 1-17 have been cancelled and new claim 18 has been added. Support for new claim 18 comes from the application as filed at least at page 11, line 30 - page 12, line 4.


Applicants respectfully request entry of the amendments and examination of the present application with the added claim. If the Examiner has any question regarding the application, he or she is invited to contact the undersigned attorney at the number indicated.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,
GENENTECH, INC.

Date: August 8, 2001

By:


Jeffrey S. Kubinec
Reg. No. 36,575
Telephone: (650) 225-8228



09157

PATENT TRADEMARK OFFICE

Serial No.: not yet assigned

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

The paragraph beginning at line 16 page 1 has been amended as follows:

[This is a continuing application under 35 U.S.C. §120/121 of the U.S.S.N. 07/209,665, which is a Continuation-in-Part of U.S.S.N. 07/110,255, filed October 20, 1987 which in turn is a Continuation-in-Part of U.S.S.N. 06/926,977, filed November 4, 1986]. This application is a continuation application under 37 C.F.R. §1.53 (b) (1) claiming priority to co-pending application Serial No. 08/476,837 filed on 7 June 1995, which is a continuation of Serial No. 08/260,662 filed on 16 June 1994, which is a continuation of Serial No. 08/076,280 filed on 11 June 1993, which is a continuation of Serial No. 07/887,575 filed on 18 May 1992, which is a continuation in part of Serial No. 07/237,595 filed on 25 August 1988 which is a continuation in part of Serial No. 07/209,665 filed on 21 June 1988 which is a continuation in part of Serial No. 06/926,977 filed 4 November 1986 which applications are incorporated herein by reference.

In the claims:

Claim 1 has been canceled.

New claim 18 has been added.